Pharma giant AstraZeneca is pledging $15bn to fund an R&D and manufacturing capacity expansion in China – marking a significant investment into a country touted as an up-and-coming pharma powerhouse. The multi-billion-dollar investment, which is set to run through to 2030, will see AstraZeneca improve its cell therapy and radioconjugate discovery, development and manufacturing capabilities in China. This will help to support the company’s pipeline ambitions across the oncology, haematology and autoimmune ...